Zydus Lifesciences LimitedNSE: ZYDUSLIFE

Press Release Aug 27 2024

· Issued by Zydus Lifesciences Limited

Filed with NSE · · 2 pages · English

Summary by 6ix AI

Zydus Lifesciences Limited has issued a press release announcing the receipt of final approval from the USFDA for Amantadine extended-release capsules in two dosages. The approval allows Zydus to market the drug, which is used for treating dyskinesia in Parkinson's disease patients. Additionally, Zydus is eligible for a period of exclusivity for the lower dosage of the drug.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Zydus Lifesciences Limited on 6ix

In the deck

Earlier from Zydus Lifesciences

Later from Zydus Lifesciences

All Zydus Lifesciences news releases